Ceryvyn Therapeutics Limited (CYVNY)
| Market Cap | 9.72M -97.9% |
| Revenue (ttm) | 692.00 -99.6% |
| Net Income | 228.60M |
| EPS | 0.17 |
| Shares Out | n/a |
| PE Ratio | 0.04 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,154 |
| Open | 0.0332 |
| Previous Close | 0.0230 |
| Day's Range | 0.0232 - 0.0332 |
| 52-Week Range | 0.0017 - 3.1700 |
| Beta | 1.49 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 26, 2026 |
About Ceryvyn Therapeutics
Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia. [Read more]
News
Ceryvyn Therapeutics Annual report: H2 2026
Ceryvyn Therapeutics has published its H2 2026 annual report on August 30, 2026.
Ceryvyn Therapeutics Slides: Investor presentation
Ceryvyn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Opthea Provides Corporate Update
Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to contin...
Opthea Announces Decision to Discontinue Wet AMD Trials
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52
Opthea Announces COAST Phase 3 Trial Topline Results
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on t...
Opthea Announces Phase 2b Wet AMD Publication
Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., ...
Opthea to Present at Oppenheimer Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therap...
Opthea Wet AMD Data Featured at Macula Society Meeting
MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea to Host Investor Days in New York and Australia
Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on Februar...
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia an...
Opthea's Wet AMD Program to be Featured at FLORetina 2024
MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea Appoints Kathy Connell to Board of Directors
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J.,...
Opthea Wet AMD Program to be Presented at Innovate Retina
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in early 202...
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea Announces Executive Leadership Changes and Senior Hires
Daniel Geffken appointed Chief Financial Officer ad interim Mike Campbell appointed Chief Commercial Officer Three senior leaders appointed for Biometrics, Clinical Operations and Market Access MELBOU...
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea Reports Full-Year Financial Results and Business Updates
Completed patient enrollment in COAST and ShORe pivotal wet AMD trials Financings extended cash runway through topline data readout of both trials in CY2025 Leadership appointments in preparation for ...
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024
MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens
Fully underwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise approximately A$55.0m (US$36.9m 1) will close at 5:00 pm (Melbourne ...
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m 1) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024
Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)
Financing extends Opthea's cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD